In the DLPFC, as expected from the descriptive results of DBH-immunoreactivity, the AD cases showed higher DBH+ load compared to controls and PD (increase by 78% and 87%, respectively, P = 0.006 and P = 0.007, both FDR-corrected), while no difference was found between PD and controls (Fig. 4b). This evidence concerns the gene DBH and Alzheimer disease.